Synthesis, characterization and Stat3 inhibitory properties of the prototypical platinum(IV) anticancer drug, [PtCl3(NO2)(NH3)2] (CPA-7) - PubMed (original) (raw)
. 2008 Apr 7;47(7):2798-804.
doi: 10.1021/ic702057q. Epub 2008 Feb 13.
Affiliations
- PMID: 18269242
- DOI: 10.1021/ic702057q
Synthesis, characterization and Stat3 inhibitory properties of the prototypical platinum(IV) anticancer drug, [PtCl3(NO2)(NH3)2] (CPA-7)
Shalyn L Littlefield et al. Inorg Chem. 2008.
Abstract
This paper describes a reinvestigation of the literature concerning the synthesis and structural characterization of the platinum(IV)-based anticancer drug known as CPA-7 and believed to be the compound fac-[PtCl3(NO2)(NH 3)2]. CPA-7 has previously been extensively investigated for its ability to control tumor cell growth by inhibition of Stat3 signaling, but very little information is available concerning its synthesis or spectroscopic properties. A reproducible synthetic route is shown to produce an active material which is characterized by IR and (1)H, (14)N, (15)N, and (195)Pt NMR spectroscopy, and single crystal X-ray crystallography. The freshly prepared drug is obtained as a single isomer which may in fact be fac- or mer-[PtCl3(NO2)(NH3)2], but recrystallization resulted in a disordered crystal containing approximately equal amounts of the two geometric isomers.
Similar articles
- Novel platinum(II) and palladium(II) complexes with cyclin-dependent kinase inhibitors: synthesis, characterization and antitumour activity.
Szucová L, Trávnícek Z, Zatloukal M, Popa I. Szucová L, et al. Bioorg Med Chem. 2006 Jan 15;14(2):479-91. doi: 10.1016/j.bmc.2005.08.033. Epub 2005 Sep 28. Bioorg Med Chem. 2006. PMID: 16198575 - Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice.
Zhang L, Alizadeh D, Van Handel M, Kortylewski M, Yu H, Badie B. Zhang L, et al. Glia. 2009 Oct;57(13):1458-67. doi: 10.1002/glia.20863. Glia. 2009. PMID: 19306372 - Basis for design and development of platinum(IV) anticancer complexes.
Hall MD, Mellor HR, Callaghan R, Hambley TW. Hall MD, et al. J Med Chem. 2007 Jul 26;50(15):3403-11. doi: 10.1021/jm070280u. Epub 2007 Jun 28. J Med Chem. 2007. PMID: 17602547 Review. No abstract available. - Platinum(IV) anticancer complexes.
Hall MD, Dolman RC, Hambley TW. Hall MD, et al. Met Ions Biol Syst. 2004;42:297-322. Met Ions Biol Syst. 2004. PMID: 15206106 Review. No abstract available.
Cited by
- MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines.
Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Xiao M, Li L, Gimotty PA, Wilson M, Hayden J, Keeney F, Nathanson KL, Herlyn M. Vultur A, et al. Oncogene. 2014 Apr 3;33(14):1850-61. doi: 10.1038/onc.2013.131. Epub 2013 Apr 29. Oncogene. 2014. PMID: 23624919 Free PMC article. - Synthetic methods for the preparation of platinum anticancer complexes.
Wilson JJ, Lippard SJ. Wilson JJ, et al. Chem Rev. 2014 Apr 23;114(8):4470-95. doi: 10.1021/cr4004314. Epub 2013 Nov 27. Chem Rev. 2014. PMID: 24283498 Free PMC article. Review. No abstract available. - Stat3 and gap junctions in normal and lung cancer cells.
Guy S, Geletu M, Arulanandam R, Raptis L. Guy S, et al. Cancers (Basel). 2014 Mar 25;6(2):646-62. doi: 10.3390/cancers6020646. Cancers (Basel). 2014. PMID: 24670366 Free PMC article. - CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3.
Liang M, Zhan F, Zhao J, Li Q, Wuyang J, Mu G, Li D, Zhang Y, Huang X. Liang M, et al. BMC Cancer. 2016 Jul 19;16:504. doi: 10.1186/s12885-016-2488-6. BMC Cancer. 2016. PMID: 27435207 Free PMC article. - SOCS3 blocks HIF-1α expression to inhibit proliferation and angiogenesis of human small cell lung cancer by downregulating activation of Akt, but not STAT3.
Wan J, Che Y, Kang N, Wu W. Wan J, et al. Mol Med Rep. 2015 Jul;12(1):83-92. doi: 10.3892/mmr.2015.3368. Epub 2015 Feb 17. Mol Med Rep. 2015. PMID: 25695729 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous